AAP
RYTM icon

Arax Advisory Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Arax Advisory Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.4K Buy
814
+446
+121% +$40.3K ﹤0.01% 2811
2026
Q1 		$32.1K Sell
368
-13
-3% -$1.26K ﹤0.01% 1865
2025
Q4 		$40.8K Sell
381
-400
-51% -$42.4K ﹤0.01% 1722
2025
Q3 		$78.9K Buy
781
+223
+40% +$20.7K ﹤0.01% 1628
2025
Q2 		$35.3K Buy
558
+40
+8% +$2.45K ﹤0.01% 1403
2025
Q1 		$27.4K Buy
518
+64
+14% +$3.55K ﹤0.01% 1169
2024
Q4 		$25.4K Buy
454
+400
+741% +$22.1K ﹤0.01% 1121
2024
Q3 		$2.83K Hold
54
– – ﹤0.01% 1929
2024
Q2 		$2.22K Buy
+54
New +$2.16K ﹤0.01% 1931

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arax Advisory Partners's RYTM Position: Q2 2026 in Review

Arax Advisory Partners increased its Rhythm Pharmaceuticals (RYTM) stake by 121% in Q2 2026, buying an estimated $40.3K and bringing the position to 814 shares worth $90.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2811.

Arax Advisory Partners first reported a position in RYTM in Q2 2024 and has held it in 9 quarters since. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Arax Advisory Partners held 814 shares of Rhythm Pharmaceuticals worth $90.4K as of Q2 2026.
  • Arax Advisory Partners bought 446 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $40.3K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2811 holding.
  • Arax Advisory Partners first reported a position in Rhythm Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.